undamentalytics Newsletter
Sign in

Anixa Biosciences Inc (ANIX) stock

Add to watchlist

Add holding +

NASDAQ: ANIX Nasdaq Biotechnology

Anixa Biosciences Inc is a US-listed company in the biotechnology industry. Its financial year ends in October.

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders4 buying, 0 selling21 purchases and 0 sales by directors and officers, last 12 monthsInsider trades
  • Funds26 adding, 14 cuttingOf 6 active managers that changed their stake, 2 added; quarter to June 30, 2026Fund buyers and sellers

The Fundamentalytics view

Current signal Operating margin compressing: TTM operating margin fell to -3112.1%, down 1599.6pp year over year.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Net cash. Cash exceeds long-term debt by $0.0bn.

Things to watch

  • Revenue shrinking. Revenue fell 58.9% over the last 12 months.
  • Loss-making. Operating margin is -3112.1%: costs exceed revenue.
  • Margins narrowing. Operating margin is down 1599.6 points on a year ago.
  • Burning cash. Free cash flow was -1177.5% of revenue over the last 12 months.
  • Heavy stock-based pay. Stock pay equals 1825.2% of revenue: a real cost that cash-flow figures leave out.
  • Share dilution. Diluted shares rose 2.4% in a year.

Latest results: FY2023 Q4

Filed January 16, 2024
Earnings per share
-$0.08 against an average estimate of -$0.08: beat by 0.0%
Next report
September 9, 2026; average EPS estimate -$0.08

Anixa Biosciences' figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day+2.3%
  • 1 week-6.7%
  • 1 month+3.7%
  • This year-4.2%
  • 1 year-26.1%
  • 5 years-44.4%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

No recent updates are available for ANIX from the sources we follow. See filings →

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Anixa Biosciences Inc valuation models and calculator

No model value for Anixa Biosciences Inc at the moment. Current status: data-quality checks not passed. Available reported financials are shown below.

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: data-quality checks not passed.

Moat

12 /100

Weak moat

How hard Anixa Biosciences's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 0 / 20

    Net income has been a median -65.9% of total assets over 10 years.

  • Durability 10 / 20

    Operating margin has been a median -594.9%; its worst year was -317265.8%.

  • Discipline 0 / 20

    The diluted share count rose 87.4% over five years; stock-based pay has been a median 1024.2% of revenue.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (17 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$0.31 +9% — 0%
Next −$0.31 0% — 0%

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is 0.0% on 90 days ago. In the last 30 days, 1 analyst raised Anixa Biosciences Inc's forecast and 0 cut it.

Consensus EPS forecast Anixa Biosciences Inc, last 90 days
−$0.40 −$0.30 −$0.20 −$0.10 $0.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$0.31 Current fiscal year, 60 days ago: −$0.31 Current fiscal year, 30 days ago: −$0.31 Current fiscal year, 7 days ago: −$0.31 Current fiscal year, Now: −$0.31 −$0.31 Next fiscal year, 90 days ago: −$0.31 Next fiscal year, 60 days ago: −$0.31 Next fiscal year, 30 days ago: −$0.31 Next fiscal year, 7 days ago: −$0.31 Next fiscal year, Now: −$0.31 −$0.31

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago −$0.31−$0.31
60 days ago −$0.31−$0.31
30 days ago −$0.31−$0.31
7 days ago −$0.31−$0.31
Now −$0.31−$0.31

Earnings against estimates

Quarter toEstimateActualSurprise
Jul 2026 −$0.08 −$0.08 0.0%
Apr 2026 −$0.10 −$0.07 +30.0%
Jan 2026 −$0.09 −$0.08 +11.1%
Oct 2025 −$0.09 −$0.09 0.0%

Adjusted EPS as companies report it, against the average analyst estimate.

Analyst recommendations

3 analysts, Oct 2026
Buy3100%
Hold00%
Sell00%

Monthly trend

  1. Oct 2026123
  2. Sep 2026134

Counts of recommendations published by analysts covering Anixa Biosciences Inc, by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
5.0%
of tradable shares
Days to cover
5.24
at average volume
Short interest, 1 month
+58%
to October 15, 2026
Held by institutions
14%
of shares
Held by insiders
5.7%
of shares
Employees
4
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
ANIX−3%+43%−9%−40%+35%−4%
Industry peers (median)−36%−57%−18%−28%−5%−27%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
ANIX42%58%58%33%50%36%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
ANIX−60%−39%−52%−56%−40%−31%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since November 2, 2015: 91% from October 28, 2016 to August 15, 2017. Getting back needed a 1025% gain, reached on March 17, 2021, 1310 days after the low.

Price behaviour

52-week range
$2.35 – $5.22
From 52-week high
−42.7%
vs 50-day average
+1.1%
vs 200-day average
+0.8%
Volatility (1 year)
66%
Beta vs S&P 500
1.48

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Fundamentals

Revenue (TTM) Anixa Biosciences Inc
$0 $5M $10M $15M FY12 Q4 FY13 Q3 FY15 Q2 FY22 Q2 Revenue (TTM), FY12 Q4: $947.1K Revenue (TTM), FY13 Q1: $500K Revenue (TTM), FY13 Q2: $252K Revenue (TTM), FY13 Q3: $2.5K Revenue (TTM), FY13 Q4: $388.9K Revenue (TTM), FY15 Q1: $12.8M Revenue (TTM), FY15 Q2: $11.7M Revenue (TTM), FY15 Q3: $10.6M Revenue (TTM), FY15 Q4: $9.3M Revenue (TTM), FY21 Q4: $512K Revenue (TTM), FY22 Q1: $512.5K Revenue (TTM), FY22 Q2: $512K $512K

Source: SEC EDGAR filings. Retrieved November 1, 2026.

View chart data
Period Revenue (TTM)
FY12 Q4 $947.1K
FY13 Q1 $500K
FY13 Q2 $252K
FY13 Q3 $2.5K
FY13 Q4 $388.9K
FY15 Q1 $12.8M
FY15 Q2 $11.7M
FY15 Q3 $10.6M
FY15 Q4 $9.3M
FY21 Q4 $512K
FY22 Q1 $512.5K
FY22 Q2 $512K
Revenue growth, TTM YoY Anixa Biosciences Inc
-100% 0% 100% 200% 300% FY12 Q2 FY12 Q4 FY13 Q2 FY13 Q4 Revenue growth, TTM YoY, FY12 Q2: 237.4% Revenue growth, TTM YoY, FY12 Q3: 61.3% Revenue growth, TTM YoY, FY12 Q4: -5.6% Revenue growth, TTM YoY, FY13 Q1: -65.2% Revenue growth, TTM YoY, FY13 Q2: -84.2% Revenue growth, TTM YoY, FY13 Q3: -99.8% Revenue growth, TTM YoY, FY13 Q4: -58.9% -58.9%

Source: SEC EDGAR filings. Retrieved November 1, 2026.

View chart data
Period Revenue growth, TTM YoY
FY12 Q2 237.4%
FY12 Q3 61.3%
FY12 Q4 -5.6%
FY13 Q1 -65.2%
FY13 Q2 -84.2%
FY13 Q3 -99.8%
FY13 Q4 -58.9%
Operating margin (TTM) Anixa Biosciences Inc
-400000% -300000% -200000% -100000% 0% 100000% FY12 Q4 FY13 Q3 FY15 Q2 FY22 Q2 Operating margin (TTM), FY12 Q4: -436.6% Operating margin (TTM), FY13 Q1: -1064.0% Operating margin (TTM), FY13 Q2: -2497.7% Operating margin (TTM), FY13 Q3: -317265.8% Operating margin (TTM), FY13 Q4: -2036.2% Operating margin (TTM), FY15 Q1: 6.1% Operating margin (TTM), FY15 Q2: -0.0% Operating margin (TTM), FY15 Q3: -12.5% Operating margin (TTM), FY15 Q4: -10.2% Operating margin (TTM), FY21 Q4: -2565.4% Operating margin (TTM), FY22 Q1: -2884.3% Operating margin (TTM), FY22 Q2: -3112.1% -3112.1%

Source: SEC EDGAR filings. Retrieved November 1, 2026.

View chart data
Period Operating margin (TTM)
FY12 Q4 -436.6%
FY13 Q1 -1064.0%
FY13 Q2 -2497.7%
FY13 Q3 -317265.8%
FY13 Q4 -2036.2%
FY15 Q1 6.1%
FY15 Q2 -0.0%
FY15 Q3 -12.5%
FY15 Q4 -10.2%
FY21 Q4 -2565.4%
FY22 Q1 -2884.3%
FY22 Q2 -3112.1%
FCF margin (TTM) Anixa Biosciences Inc
-150000% -100000% -50000% 0% 50000% FY11 Q4 FY12 Q3 FY13 Q2 FY22 Q2 FCF margin (TTM), FY11 Q4: -72.3% FCF margin (TTM), FY12 Q1: -53.5% FCF margin (TTM), FY12 Q2: -58.4% FCF margin (TTM), FY12 Q3: -207.2% FCF margin (TTM), FY12 Q4: -331.8% FCF margin (TTM), FY13 Q1: -675.3% FCF margin (TTM), FY13 Q2: -1347.2% FCF margin (TTM), FY13 Q3: -145429.6% FCF margin (TTM), FY15 Q4: 14.1% FCF margin (TTM), FY21 Q4: -964.5% FCF margin (TTM), FY22 Q1: -968.8% FCF margin (TTM), FY22 Q2: -1177.5% -1177.5%

Source: SEC EDGAR filings. Retrieved November 1, 2026.

View chart data
Period FCF margin (TTM)
FY11 Q4 -72.3%
FY12 Q1 -53.5%
FY12 Q2 -58.4%
FY12 Q3 -207.2%
FY12 Q4 -331.8%
FY13 Q1 -675.3%
FY13 Q2 -1347.2%
FY13 Q3 -145429.6%
FY15 Q4 14.1%
FY21 Q4 -964.5%
FY22 Q1 -968.8%
FY22 Q2 -1177.5%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-K/A, 10-Q, 10-Q/A. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2010 Oct 2010 2011 Oct 2011 2012 Oct 2012 2013 Oct 2013 2014 Oct 2014 2015 Oct 2015 2016 Oct 2016 2017 Oct 2017 2018 Oct 2018 2019 Oct 2019 2021 Oct 2021 2023 Oct 2023 2024 Oct 2024
Income
Revenue 1 1 1 0 4 9 0 0 1 0 1 0 0
EBITDA −5 −5 −4 — — −1 −4 −6 −14 −12 — — —
Operating income −5 −5 −4 −8 −5 −1 −5 −6 −14 −12 −13 −11 −14
Net income −5 −7 −4 −10 −10 −1 −5 −5 −14 −12 −13 −10 −13
Diluted EPS −$0.03 −$1.00 −$0.02 −$0.05 −$1.10 −$16.00 −$0.57 −$0.58 −$0.79 −$0.59 −$0.45 −$0.32 −$0.39
Growth (year on year)
Revenue — +37.3% −6.3% −58.6% +843.1% +152.4% −96.8% +20.8% +206.9% −77.5% +104.8% −59.0% 0.0%
Margins
EBITDA margin −717.1% −500.4% −439.1% — — −10.1% <−999% <−999% <−999% <−999% — — —
Operating margin −718.3% −501.2% −439.8% <−999% −137.5% −10.2% <−999% <−999% <−999% <−999% <−999% <−999% <−999%
Net margin −708.3% −735.5% −452.4% <−999% −261.9% −14.9% <−999% <−999% <−999% <−999% <−999% <−999% <−999%
Free-cash-flow margin −329.5% −72.3% −334.3% — −65.1% 14.1% <−999% <−999% −387.6% <−999% −964.5% <−999% <−999%
Cash flow
Cash from operations −2 −1 −3 −3 −2 1 −3 −4 −4 −5 −5 −6 −7
Capital spending 0 0 0 — 0 0 0 0 0 0 0 0 0
Free cash flow −2 −1 −3 — −2 1 −4 −4 −4 −5 −5 −6 −7
Stock-based pay 1 2 1 3 2 3 — −2 −9 −6 8 4 4
Free cash flow after stock pay −3 −3 −4 — −5 −1 — −2 5 1 −12 −11 −12
Balance sheet
Cash 1 1 0 1 3 4 2 3 3 3 29 1 1
Total debt 0 0 0 1 2 1 — 0 0 0 0 0 0
Net debt (negative = net cash) −1 −1 −0 −0 −1 −4 −2 −3 −3 −3 −29 −1 −1
Diluted shares — 7m 7m 8m 9m 9m 9m 12m 18m 20m 29m 31m 32m
Returned to shareholders
Buybacks — — — — — — — — — — — — 0
Total returned — — — — — — — — — — — — 0

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Competitors: side by side with peers

Closest by revenue in biotechnology
Last 12 months unless stated ANIX CRDF CRVO MNOV STTK LGVN Median
Revenue, last 12 months $512000 $508000 $331295 $920481 $1m $1m $55m
Revenue growth, last 12 months −58.9% −7.0% −95.7% 875.7% −66.6% −42.7% 12.2%
Revenue growth, 3-year average −28.4% 7.2% −52.7% — 5.2% 10.4% 13.1%
Revenue growth, latest quarter −100.0% −14.0% −100.0% 240.6% −66.6% −9.2% 10.2%
Gross margin — 100.0% 100.0% 100.0% — 69.8% 82.9%
Operating margin <−999% <−999% <−999% <−999% <−999% <−999% −191.1%
Operating margin, 3-year average <−999% <−999% <−999% −905.8% <−999% <−999% −365.3%
Net margin <−999% <−999% <−999% <−999% <−999% <−999% −172.8%
Cash from operations / revenue <−999% <−999% <−999% −989.7% <−999% <−999% −168.8%
Free-cash-flow margin <−999% <−999% — −991.2% <−999% <−999% −168.1%
Free-cash-flow margin, 3-year average <−999% <−999% — <−999% <−999% <−999% −313.4%
Stock pay / revenue >999% >999% 393.0% 100.3% 853.2% 132.8% 20.7%
Change in share count 2.4% 15.8% 8.4% 0.2% 15.3% — 8.1%

Median of all 185 companies we cover in biotechnology. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Who owns it

Funds buying and selling
Reported value
$14.9M
Institutions reporting
60
Shares held vs prior quarter
▲ 5.0%
Positions opened / closed
10 / 7

Top buyers and sellers, Q2 2026: 26 institutions bought and 14 sold ; the biggest buyer was Marshall Wace, LLP (+155K shares) and the biggest seller Susquehanna International Group, LLP (−99K). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Vanguard Capital Management LLC $3.7M 1.3M 24.9% ▲ 1.1%
UBS Group AG $1.6M 585K 11.0% ▲ 6.1%
Laird Norton Wetherby Trust Company, LLC $1.6M 579K 10.8% ▲ 2.2%
D.A. Davidson & Co. $1.5M 539K 10.1% 0.0%
Geode Capital Management, LLC $1M 359K 6.7% ▼ 1.5%
Marshall Wace, LLP $919,332 328K 6.2% ▲ 89.6%
Blackrock, Inc. $559,314 200K 3.7% ▲ 17.4%
Vanguard Fiduciary Trust Co $538,597 192K 3.6% ▲ 0.7%
State Street Corp $445,312 159K 3.0% 0.0%
Gsa Capital Partners LLP $329,000 117K 2.2% ▲ 18.8%
LPL Financial LLC $312,298 112K 2.1% ▲ 37.7%
Northern Trust Corp $193,858 69K 1.3% ▲ 3.6%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Anixa Biosciences Inc's complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $521,772 21 trades by 4 insiders, last 12 months Insider sales History → $0 0 trades by 0 insiders
Net ▲ $521,772 net buying
Insider Date Trade Shares Price Value
Kumar Amit Chief Executive Officer October 30, 2026 Buy 5,000 $3.17 $15,850
Titterton Lewis H Jr Director October 23, 2026 Buy 8,000 $2.98 $23,840
Kumar Amit Chief Executive Officer October 22, 2026 Buy 8,000 $2.72 $21,760
Catelani Michael President, COO, & CFO September 30, 2026 Buy 5,500 $2.84 $15,620
Baskies Arnold M Director September 24, 2026 Buy 5,000 $2.76 $13,800
Kumar Amit Chief Executive Officer September 24, 2026 Buy 7,000 $2.78 $19,460
Titterton Lewis H Jr Director September 23, 2026 Buy 49,036 $2.69 $131,907
Kumar Amit Chief Executive Officer September 10, 2026 Buy 5,000 $2.76 $13,800
Titterton Lewis H Jr Director September 10, 2026 Buy 10,000 $2.73 $27,300
Kumar Amit Chief Executive Officer September 10, 2026 Buy 3,000 $2.75 $8,250
Kumar Amit Chief Executive Officer July 31, 2026 Buy 5,000 $3.47 $17,350
Kumar Amit Chief Executive Officer July 27, 2026 Buy 3,188 $3.37 $10,744

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Recent SEC filings

Data status

When each part of this page on Anixa Biosciences Inc was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Anixa Biosciences Inc in brief

What does Anixa Biosciences Inc do?
Anixa Biosciences Inc is a US-listed company in the biotechnology industry. Its financial year ends in October.
What is Anixa Biosciences Inc's stock ticker?
Anixa Biosciences Inc trades under the ticker ANIX on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
Who are Anixa Biosciences Inc's largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Vanguard Capital Management LLC, UBS Group AG and Laird Norton Wetherby Trust Company, LLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is Anixa Biosciences Inc's market cap?
On October 31, 2024, Anixa Biosciences Inc's market capitalisation was about $112M and net debt of -$1.3M. Market figures come from third-party market data and may be delayed.
Who are Anixa Biosciences Inc's competitors?
In our Biotechnology peer group, the companies closest to Anixa Biosciences Inc are Cardiff Oncology, Inc., Cervomed Inc., Medicinova Inc, Shattuck Labs, Inc. and Longeveron Inc. The side-by-side comparison below sets their revenue, margins and growth against Anixa Biosciences Inc's.
Are insiders buying or selling Anixa Biosciences Inc stock?
Over the last 12 months, Anixa Biosciences Inc's directors and officers reported 21 open-market purchases and 0 sales on Form 4. The insider trading page charts every trade.